Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance-Reference-Cited by-同舟云学术

Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance

Published:2023-03-23 Issue:8 Volume:23 Page:801-817
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Meijboom Rosanne W¹²,Barbier Liese³,Druedahl Louise C⁴,Sarnola Kati⁵,Tolonen Hanna M⁶⁷,Gardarsdottir Helga²⁸⁹,Egberts Toine C G²⁸,Giezen Thijs J¹²¹⁰

Affiliation:

1. Pharmacy Foundation of Haarlem Hospitals, Haarlem, The Netherlands

2. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands

3. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

4. Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), Faculty of Law, University of Copenhagen, Copenhagen, Denmark

5. Research at Kela, Social Insurance Institution of Finland (Kela), Helsinki, Finland

6. HUS Pharmacy, HUS Helsinki University Hospital, and University of Helsinki, Helsinki, Finland

7. Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland

8. Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands

9. Department of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland

10. Department of Clinical Pharmacy, Spaarne Gasthuis, Haarlem and Hoofddorp, The Netherlands

Funder

the Collaborative Research Program for Biomedical Innovation Law, a scientifically independent research program supported by the Novo Nordisk Foundation

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2189008

Reference35 articles.

1. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

2. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases

3. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease

5. European Medicines Agency. Guideline on similar biological medicinal products. 2014;

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market;Expert Opinion on Biological Therapy;2024-06-06